About Drug Repurposing
The Drug Repurposing category is part of the AI Drug Discovery market map, tracking 11 companies building in this segment. Target discovery, molecular design, protein folding, and clinical trial optimization accelerating the path from lab to patient. Curated by Hartmann Capital's venture research team.
Companies in Drug Repurposing
- Healx — Series C, $80M
- BioXcel Therapeutics — Public, $60M
- Lantern Pharma — Public, $26M
- NuMedii — Series A, $6M
- twoXAR — Series A, $10M
- Aria Pharmaceuticals — Series A, $20M
- OpenTargets — Non-Profit
- Barinthus Bio — Series A, $25M
- Pharnext — Public, $147M
- Plex Research — Seed
- CytoReason — Series C, $80M
Frequently Asked Questions
- What companies are in the Drug Repurposing category?
- The Drug Repurposing category includes 11 companies: Healx, BioXcel Therapeutics, Lantern Pharma, NuMedii, twoXAR, Aria Pharmaceuticals, OpenTargets, Barinthus Bio, Pharnext, Plex Research, CytoReason. This is part of the AI Drug Discovery market map maintained by Hartmann Capital.
- How many Drug Repurposing startups are tracked?
- Hartmann Capital tracks 11 companies in the Drug Repurposing segment of the AI Drug Discovery market map.
- What are the best funded Drug Repurposing companies?
- Top funded companies in Drug Repurposing include Pharnext ($147M), Healx ($80M), CytoReason ($80M), BioXcel Therapeutics ($60M), Lantern Pharma ($26M). Browse the full list in the AI Drug Discovery market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.